Fresenius Medical Care AG & Co. KGaA ADR (FMS)
Here's Why Fresenius (FMS) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Fresenius Medical Care: Let's Look At The Upside
Fresenius Medical Care is a BBB-rated leader in kidney care with a 3.1% yield, undervalued at 14x P/E, and poised for growth by 2025-2026E. Despite recent earnings declines, the company expects growth in 2024, driven by global ESRD demand, at-home treatments, and strategic divestments. Political risks exist, but Fresenius' market-leading position, leverage improvements, and 35% market share in equipment support a "Buy" rating with a $34/share PT.
Here's Why Fresenius (FMS) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives
Fresenius Medical Care's diversified portfolio helps to fight competition and maintain market leadership.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Fresenius Medical Care Stock Rises on NxStage VersiHD Launch
FMS introduces NxStage VersiHD with GuideMe Software to simplify home dialysis and grow its patient base in the United States.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
FMS continues to gain traction through its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
Fresenius Medical (FMS) Q2 Earnings In Line, Operating Margin Up
Fresenius Medical's (FMS) second-quarter revenues suffer due to divestures. However, the company?
Fresenius Medical Care AG (FMS) Q2 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q2 2024 Earnings Call July 30, 2024 8:00 AM ET Company Participants Dominik Heger - Head, Investor Relations Helen Giza - Chief Executive Officer and Chair Martin Fischer - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi Richard Felton - Goldman Sachs Graham Doyle - UBS Hassan Al-Wakeel - Barclays Victoria Lambert - Berenberg Hugo Solvet - BNP Paribas James Vane-Tempest - Jefferies David Adlington - JPMorgan Falko Friedrichs - Deutsche Bank Robert Davies - Morgan Stanley Marianne Bulot - Bank of America Dominik Heger Thank you, Alice. Good morning, good afternoon or good evening, depending on where you are.
Here's Why Fresenius (FMS) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
